[go: up one dir, main page]

UA91281U - Method for manufacturing drug formulation possessing pronounced antigestagenic activity - Google Patents

Method for manufacturing drug formulation possessing pronounced antigestagenic activity

Info

Publication number
UA91281U
UA91281U UAU201401313U UAU201401313U UA91281U UA 91281 U UA91281 U UA 91281U UA U201401313 U UAU201401313 U UA U201401313U UA U201401313 U UAU201401313 U UA U201401313U UA 91281 U UA91281 U UA 91281U
Authority
UA
Ukraine
Prior art keywords
drug formulation
manufacturing
antigestagenic activity
manufacturing drug
excipients
Prior art date
Application number
UAU201401313U
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Ніколай Борісовіч Сорокін
Original Assignee
Ніколай Борісовіч Сорокін
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ніколай Борісовіч Сорокін filed Critical Ніколай Борісовіч Сорокін
Priority to UAU201401313U priority Critical patent/UA91281U/en
Publication of UA91281U publication Critical patent/UA91281U/en

Links

Landscapes

  • Medicinal Preparation (AREA)

Abstract

A method for manufacturing the drug formulation containing one or more dosage units of the Mifepriston-based pharmaceutical composition possessing the pronounced antigestagenic activity comprises weighing and sieving the powders of the active ingredient and excipients, mixing the said powders followed by the compression process resulting in tabletted dosage units of the drug formulation. The microcrystalline cellulose, sodium carboxymethyl starch, and calcium stearate or magnesium stearate are used as the excipients. The direct compression process with dedusting is used for manufacturing the tablets.
UAU201401313U 2014-02-10 2014-02-10 Method for manufacturing drug formulation possessing pronounced antigestagenic activity UA91281U (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
UAU201401313U UA91281U (en) 2014-02-10 2014-02-10 Method for manufacturing drug formulation possessing pronounced antigestagenic activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
UAU201401313U UA91281U (en) 2014-02-10 2014-02-10 Method for manufacturing drug formulation possessing pronounced antigestagenic activity

Publications (1)

Publication Number Publication Date
UA91281U true UA91281U (en) 2014-06-25

Family

ID=56283039

Family Applications (1)

Application Number Title Priority Date Filing Date
UAU201401313U UA91281U (en) 2014-02-10 2014-02-10 Method for manufacturing drug formulation possessing pronounced antigestagenic activity

Country Status (1)

Country Link
UA (1) UA91281U (en)

Similar Documents

Publication Publication Date Title
MX2020002841A (en) High dosage valbenazine formulation and compositions, methods, and kits related thereto.
MX2011007817A (en) Controlled release pharmaceutical or food formulation and process for its preparation.
PH12020550815A1 (en) Delayed release deferiprone tablets and methods of using the same
MY174005A (en) Swallowable n-acetylcysteine tablets
PH12015500823A1 (en) Modified release formulations for oprozomib
HK1214519A1 (en) Dual use oral pharmaceutical composition tablets of sulfate saltes and methods of use thereof
EP3648745A4 (en) Pharmaceutical composition including multi-unit spheroidal tablet containing esomeprazole and spheroidal pharmaceutically acceptable salt thereof, and method of preparing the pharmaceutical composition
EA202090913A1 (en) COMPOSITION OF MODIFIED RELEASE TABLETS CONTAINING MIRABEGRON
WO2019240699A3 (en) Tablet formulations comprising metformin and sitagliptin processed with hot-melt extrusion
PH12016500120A1 (en) Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation
PH12016502272A1 (en) Ceritinib formulation
MX2018010065A (en) Oral dosage form comprising rifaximin in form beta.
SA516370446B1 (en) Anti-tuberculosis stable pharmaceutical composition in a form of a dispersible tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation
UA91281U (en) Method for manufacturing drug formulation possessing pronounced antigestagenic activity
EA201600242A1 (en) PHARMACEUTICAL COMPOSITION IN THE FORM OF A TABLET AND METHOD FOR ITS PREPARATION
UA91283U (en) Drug formulation possessing pronounced antigestagenic activity
RU2013107724A (en) PHARMACEUTICAL COMPOSITIONS OF MONTELUKAST AND LEVOCETIRISINE
TW201613586A (en) Pharmaceutical dosage forms
BR112013000870A2 (en) oral pharmaceutical dosage form tablets
UA97982U (en) DRESSING MEDICINE FOR TABLETS
PH12020550597A1 (en) Formulation having improved hygroscopic property and dissolution rate comprising telmisartan or its pharmaceutically acceptable salt
MX2020012408A (en) Novel pharmaceutical composition of tamsulosin and dutasteride.
UA120295U (en) ANTI-THROMBOCITARY ACTION MEDICINAL PRODUCT
PH12018501392A1 (en) Pharmaceutical composite preparation
RU2013118917A (en) MEDICINAL FORM CONTAINING DESLORATADINE AND METHOD FOR PRODUCING IT